Tianjin Chasesun Pharmaceutical Co., Ltd.

Tianjin Chasesun Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company listed on the ChiNext board of the Shenzhen Stock Exchange since 2009. The company specializes in a diverse range of products and services within the pharmaceutical sector, including traditional Chinese medicine (TCM) formula granules, finished drug products, medical devices, drug substances and excipients, healthcare services, and intelligent pharmaceutical and medical device supply chain services. The company's TCM formula granules business focuses on modernizing traditional decoctions through innovative processing techniques. In the finished drug products segment, it emphasizes independent innovation alongside the development of generic and innovative drugs. Its medical devices subsidiary, ChoiceMMed, offers a variety of electronic medical devices for healthcare monitoring. The drug substances and excipients segment is dedicated to optimizing product offerings through research and development, while the healthcare services division aims to enhance access to TCM resources via a digital platform. Lastly, the intelligent supply chain business leverages technology to streamline logistics and management processes in the pharmaceutical sector.

1. As for the TCM formula granules business, during the reporting period, the company continued to accelerate the development, application, and filing of national and provincial standards for TCM formula granules to further expand the coverage of product varieties across regions and enhance market competitiveness. Meanwhile, the company advanced academic marketing and brand building, expanded terminal coverage and channel penetration, and enhanced customer service capabilities. These efforts enabled the company to actively respond to the quality improvement and expanded implementation of centralized procurement for formula granules and capture market opportunities. 2. As for the finished drug products business, during the reporting period, the project titled "Key Technologies for Safety Evaluation and Promotion of Combined Use of Traditional Chinese Medicine Injections" won the 2025 Science and Technology Award of the Chinese Association of Integrative Medicine, one of the most influential awards in the field. This recognition provides solid scientific support for rational clinical medication use. New specifications of Sarpogrelate Hydrochloride Tablets and Anruotai (soft-bag formulation) were rapidly launched, further enriching the company's product portfolio. Additionally, Thymalfasin for Injection passed the quality and efficacy consistency evaluation for generic injections, providing valuable experience for the subsequent development and consistency evaluation of other generic products. A study on Xuebijing Injection was published in a Lancet-family journal, precisely revealing its differentiated therapeutic benefits in patients with different sepsis subtypes. The study enabled precision treatment based on clinical phenotypes, provided a Chinese solution for personalized intervention in sepsis, and supported performance growth. 3. As for the medical devices business, during the reporting period, the project "Lightweight Intelligent Multi-parameter Detector Based on Multimodal Biosignals and AI-driven Technology" was successfully shortlisted for the Ministry of Industry and Information Technology's 2025 AI Medical Device Innovation Task Shortlist. The invention patent application filed by Tianjin ChoiceMMed, "A Method and Device for Measuring Respiratory Rate Based on PPG Signals", received the 2025 Tianjin Patent Excellence Award. In addition, the multi-parameter telemetry monitoring system obtained the Medical Device Registration Certificate, further enriching the company's product portfolio. Lanzhou Wenhe, a holding subsidiary of the company, advanced five patent authorization applications and completed the registration change for its "Disposable Nasal Oxygen Cannula". By strengthening technical reserves and continuously expanding product offerings, it drove the sustainable development of this business segment. 4. As for the drug substances and excipients business, during the reporting period, Zhanwang Pharmaceutical, a wholly-owned subsidiary of the company, successfully completed the renewal registration of three drug substances, namely dibasic calcium phosphate, methotrexate, and calcium folinate. It also submitted filing application materials for two excipients, N-methyl-2-pyrrolidone and hypromellose acetate succinate. The inspection-exemption application for the compound coating agent for food additives passed review and the product officially entered production. In addition, the drug substance iron protein succinylate passed the associated review by the Center for Drug Evaluation of the NMPA, marking new progress in drug registration and compliance, and further optimizing the company's product structure. Meanwhile, Zhanwang Pharmaceutical successfully passed the re-evaluation as a national-level specialized, sophisticated, distinctive and innovative "Little Giant" enterprise. Enoray, a holding subsidiary of the company, received a certificate from the China Biochemical Pharmaceutical Industry Association for participating in the drafting of the Guidelines for Pharmaceutical Research and Technical Evaluation of Generic Low-Molecular-Weight Heparin Drugs. Additionally, it passed the U.S. Food and Drug Administration (FDA) on-site cGMP inspection with zero Form 483 observations and was recognized as a Hubei Province Manufacturing Single Champion Enterprise. 5. As for the healthcare services business, during the reporting period, the company's intelligent remote healthcare model was successfully implemented, achieving breakthroughs in partnerships with chain pharmacies and promoting large-scale expansion through joint operations. It also explored, for the first time, a new cooperation model with public hospitals by establishing a mutually beneficial entrusted operation model integrating internet hospital development, intelligent remote system empowerment, and private-domain operations and conversion, thereby driving business growth. For its offline clinics, the company developed pediatric ADHD as a specialty area, with 10 clinics obtaining medical insurance designation. At the same time, it promoted cost reduction and efficiency improvement in clinic operations, thereby enhancing the overall economic performance of the healthcare services business. 6. As for the intelligent pharmaceutical and medical device supply chain business, during the reporting period, the company strengthened compliance management, enhanced full-level operational monitoring across its business operations, directed advantageous resources toward its core businesses, and promoted business optimization and upgrading.